Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Lantheus Holdings Inc(LNTH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LNTH
10/28/2026: LNTH (3-star) is currently NOT-A-BUY. Pass it for now.
Lantheus Holdings is a specialized healthcare company focused on providing diagnostic and therapeutic imaging agents that support critical oncology and cardiovascular care. Its main business strength is the success of its PYLARIFY imaging agent, which has captured a leading position in the prostate cancer diagnostic market. The company's primary investment story centers on its growth as a precision medicine provider, leveraging its commercial expertise to expand into theranostics. Key risks include the concentration of revenue in a few products, intense competition from larger firms, and the regulatory complexity of radiopharmaceuticals. This stock may suit growth-oriented investors, while developments in the oncology pipeline and regulatory updates remain essential metrics to monitor.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company's focus on high-growth oncology diagnostic markets aligns well with growth-oriented investment strategies. |
| Momentum investor | Strong fit while signal remains positive | The stock has demonstrated significant trend potential driven by product uptake and market momentum. |
| Value investor | Mixed fit | Valuation often reflects high growth expectations, which may not align with traditional value metrics. |
| Dividend investor | Weak fit | The company does not currently pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | The inherent volatility of biotech and radiopharmaceutical stocks poses risks not ideal for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock's valuation is sensitive to news regarding product adoption and competitive entries. |
| Valuation risk | Medium / high | High growth multiples mean the stock price is vulnerable to shifts in investor sentiment or earnings misses. |
| Competition risk (radiopharmaceuticals) | High | Lantheus faces direct competition from both large pharma and emerging diagnostic firms. |
| Business quality | Medium | While the core business is robust, the company is still transitioning its portfolio mix. |
| Dividend income | Low / none | Investors receive no current income from dividends. |
| Execution risk | Medium | Continued success depends on navigating complex regulatory environments and supply chain logistics. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -19.61% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.54B USD | Price to earnings Ratio 24.25 | 1Y Target Price 106.99 |
Price to earnings Ratio 24.25 | 1Y Target Price 106.99 | ||
Volume (30-day avg) 1.0M shares | Beta -0.06 | 52 Weeks Range 50.16 - 111.86 | Updated Date 10/28/2026 |
52 Weeks Range 50.16 - 111.86 | Updated Date 10/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.13 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Diagnostic Imaging Agents | Includes DEFINITY and other imaging agents used in clinical diagnostics. | The company generates stable revenue from products used in routine cardiac and medical imaging procedures. |
| Oncology Diagnostics | Includes the PYLARIFY imaging agent for prostate cancer. | This is the primary growth driver for the company, capturing value from the rising demand for precision cancer diagnostics. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When Before Market | Estimate 1.01 | Actual - |
Profitability
Profit Margin 17.69% | Operating Margin (TTM) 25.82% |
Management Effectiveness
Return on Assets (TTM) 8.38% | Return on Equity (TTM) 22.22% |
Valuation
Trailing PE 24.25 | Forward PE 14.24 | Enterprise Value 6.56B | Price to Sales(TTM) 4.2 |
Enterprise Value 6.56B | Price to Sales(TTM) 4.2 | ||
Enterprise Value to Revenue 4.21 | Enterprise Value to EBITDA 13.91 | Shares Outstanding 65.30M | Shares Floating 58.61M |
Shares Outstanding 65.30M | Shares Floating 58.61M | ||
Percent Insiders 1.73 | Percent Institutions 115.3 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.